Edition:
India

ITV PLC (ITV.L)

ITV.L on London Stock Exchange

165.95GBp
3:50pm IST
Change (% chg)

2.35 (+1.44%)
Prev Close
163.60
Open
163.80
Day's High
166.10
Day's Low
163.45
Volume
1,547,821
Avg. Vol
15,333,005
52-wk High
183.10
52-wk Low
141.00

Latest Key Developments (Source: Significant Developments)

ITV says talking to potential partners for new SVOD offer
Wednesday, 25 Jul 2018 

July 25 (Reuters) - ITV PLC ::CEO SAYS ACTIVELY REVIEWING SVOD OFFER, TALKING TO POTENTIAL PARTNERS.CEO SAYS COMPANY WILL CONTINUEBTO GROW ORGANICALLY, WILL LOOK AT M&A IN A VERY DISCIPLINED WAY.CEO SAYS THERE IS A REAL DEMAND FOR DISTINCTIVE BRITISH CONTENT.CEO SAYS WILL PURSUE A 'BUILD' STRATEGY IN ITS STUDIO BUSINESS, WILL IMPROVE MONETISATION OF FORMATS.  Full Article

ITV Considering Entering Into 1 Bln Pounds Joint Venture With BBC By Buying Half Of Dave Broadcaster UKTV - Telegraph
Tuesday, 29 May 2018 

May 28 (Reuters) - :ITV CONSIDERING ENTERING INTO A 1 BILLION POUNDS JOINT VENTURE WITH BBC BY BUYING HALF OF DAVE BROADCASTER UKTV - TELEGRAPH.  Full Article

Easyjet's Chief Commercial Officer To Leave
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - Easyjet Plc ::CREATING A NEW ROLE OF CHIEF DATA OFFICER TO LEAD AND COORDINATE ALL OF THE AIRLINE’S MANAGEMENT OF DATA.PAUL MOORE, EASYJET’S COMMUNICATIONS DIRECTOR,HAS RESIGNED FROM EASYJET TO JOIN ITV‍​.PETER DUFFY, THE AIRLINE’S CHIEF COMMERCIAL OFFICER HAS AGREED THAT NOW IS THE RIGHT TIME FOR HIM TO LEAVE EASYJET.  Full Article

easyJet announces appointment of Johan Lundgren as CEO​
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Easyjet Plc :APPOINTMENT OF CHIEF EXECUTIVE OFFICER.‍APPOINTMENT OF CHIEF EXECUTIVE OFFICER​.‍ANNOUNCE APPOINTMENT OF JOHAN LUNDGREN AS CEO​.‍JOHAN WILL BE JOINING BOARD OF EASYJET PLC AS A DIRECTOR AND CEO ON 1 DECEMBER​.‍CAROLYN MCCALL HAD ADVISED BOARD OF HER INTENTION TO LEAVE EASYJET IN ORDER TO BECOME CEO OF ITV PLC.​.  Full Article

UPDATE 1-Mining shares drag Britain's FTSE lower, but ITV shines

* Indivior plunges on warning of bigger hit from copycat drug (Adds closing prices)